Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01252732
Recruitment Status : Completed
First Posted : December 3, 2010
Last Update Posted : June 26, 2013
Information provided by (Responsible Party):
The Medicines Company